500 tumor mutations are tested in colon cancer. This includes KRAS, NRAS, BRAF and Microsatellite Instability (MSI) markers. BRAF inhibitors (Sorafenib, Nexavar and Vemurafenib) are available to treat patients with colon cancer. BRAF mutations in colorectal cancer.
Colon cancer tumor markers. Precision medicine for every patient. KRAS, NRAS, BRAF mutations in colon cancer. Leading German-American colorectal cancer oncologist discusses progress in colon cancer tumor mutations profiling. Every colorectal cancer patient should be tested for the molecular profile of colon cancer tumor. Colon cancer tumor profile includes 50 gene panel for diagnosis of colorectal cancer. Larger tumor gene profile panels available that test 400 or 500 genetic alterations in colon cancer tumor. Colorectal cancer targeted chemotherapy options depend on precise diagnosis. Advanced stage 4 colon cancer treatment by EGFR inhibitors and BRAF inhibitors. Medical second opinion confirms colorectal cancer diagnosis at genetic level. Medical second opinion also confirms colon cancer cure is possible in metastatic colon cancer. Best BRAF, NRAS, KRAS, MSI-driven precision medicine treatment for advanced stage 4 colon cancer with metastatic lesions. Medical second opinion helps to select a personalized medicine targeted treatment for stage 4 colorectal cancer with liver or lung metastases. Get medical second opinion on advanced colorectal cancer. Be confident that your precision medicine treatment is the best. Best colorectal cancer treatment by new BRAF inhibitors (Sorafenib, Nexavar and Vemurafenib), EGFR inhibitor monoclonal antibodies, anti-angiogenesis medications and multikinase inhibitors. Video interview with leading expert in metastatic colorectal cancer treatment from California. Colon cancer tumor markers. KRAS, NRAS, BRAF mutations in colon cancer. Dr. Anton Titov, MD. Personalized medicine, precision medicine is already here. Colon cancer and rectal cancer require personalized treatment as you have just discussed. Surgery cures about half of colon cancer and rectal cancer patients with resectable tumors. But the cancer usually returns in the other 50% of colon cancer patients. That's the reason to do adjuvant chemotherapy after the surgery to remove the colon cancer or rectal cancer tumor. It is very important to discover patients with aggressive colon cancer. They will likely have more aggressive disease. Who is more likely to have a recurrence of colon cancer or rectal cancer? Molecular markers for colorectal cancer are used for this purpose. You are one of the leaders in molecular profiling of colorectal cancer. What is the current status of molecular tumor markers in colorectal cancer? What advantages testing individual patients for colon cancer tumor markers will bring in the future? Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). Today a patient who is diagnosed with colon cancer should be tested for the molecular profile. Particularly patients with metastatic colorectal cancer. Because testing the molecular profile of colon cancer tumor will give oncologist and patient the option to review precision treatment strategies for colorectal cancer. It's important to establish the treatment goal for colon cancer. But the treatment strategy for colon cancer needs to be determined by the molecular makeup of the tumor. We have really only one validated molecular marker. We use it routinely for colon cancer patients. These molecular tumor markers are KRAS and NRAS. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). These molecular tests in colon cancer will allow us to decide whether EGFR inhibitors will be effective or not. Now we are looking at many more molecular markers of colon cancer tumors. These additional molecular tumor markers are now part of new tumor profiling gene mutation panels. These tumor markers are used around the world. Usually, in our clinical colon cancer treatment practice we use at least a 50 gene panel. But there are now tumor gene profile panels available from different companies. Such tumor profile panels are testing 400 or 500 genetic alterations in colon cancer tumor at once. Some molecular tumor markers are more important than others. But these colon cancer tumor gene profile panel tests reflect many of the genes. They reflect proteins or pathways that can be targeted by colon cancer treatments. The problem is that the frequency of these genetic alterations may be very low. We need in the future to test all colon cancer patients. Then we can understand the molecular makeup of each individual colon cancer tumor. We then can make the best decision for the most effective treatment. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). Now there is a very good example. It shows how important it is to go beyond molecular tumor markers KRAS and NRAS. This is the mutation in the oncogene called BRAF. BRAF is a very important prognostic factor. BRAF mutation presence in the colon cancer tumor indicates really shortened overall survival. Colon cancer tumors with BRAF mutations don't respond very well to all the treatments. But now there are BRAF inhibitors available (Sorafenib, Nexavar and Vemurafenib). Clinical trials this have been recently presented at ASCO and at ESMO international meetings. They show very promising efficacy data. Patients were treated by chemotherapy medications. We already have BRAF inhibitors (Sorafenib, Nexavar and Vemurafenib). Colon cancer is a disease that was very difficult to treat. It suddenly shows very promising treatments. We use new targeted cancer medications based on molecular tumor profile testing. Colon cancer tumor markers. 50 to 500 colon cancer tumor marker panels can help select personalized colorectal cancer treatment. KRAS, NRAS, BRAF, MSI genes.